Hi,Regarding last year's presentation, comercialisation of dermacan will start early in 2022 in the United States and South Africa.What does the board think, will this (combined with reducing the cash burn) move AusCann to a positive cash flow?My hope is still CPAT1 but this will still take years.
Cheers
Nauscher
- Forums
- ASX - By Stock
- AC8
- Ann: December 2021 Quarterly Activities and Cashflow Reports
Ann: December 2021 Quarterly Activities and Cashflow Reports, page-15
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AC8 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online